Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History XBIO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics XBIO

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Xenetic Biosciences Inc

XBIO
Current price
4.11 USD +0.13 USD (+3.27%)
Last closed 3.93 USD
ISIN US9840155033
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 5 705 918 USD
Yield for 12 month +4.58 %
1Y
3Y
5Y
10Y
15Y
XBIO
21.11.2021 - 28.11.2021

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. The company's proprietary DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression, pancreatic ductal adenocarcinoma, colorectal carcinoma, and other gastrointestinal cancer. Its product pipeline includes XBIO-015 for treating pancreatic carcinoma and solid tumors; and XBIO-020 for treating solid tumors. The company also has partnered with biotechnology and pharmaceutical companies to develop its proprietary drug delivery platform, PolyXen, which as an enabling platform technology for protein and peptide drug delivery. It has collaboration agreements with Belgian Volition SARL Limited to develop NETs-targeted adoptive cell therapies for the treatment of cancer, as well as PJSC Pharmsynthez and Serum Institute of India to develop and launch ErepoXen for the treatment of anemia in chronic kidney disease patients; sublicensing agreement with Takeda Pharmaceutical Co. Ltd; exclusive sublicense agreement with CLS Therapeutics Ltd to develop DNase technology for the treatment of immunotherapies. The company offers under XDNASE, XCART, OncoHist, PolyXen, ErepoXen, and ImuXen trandemarks. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts. Address: 945 Concord Street, Framingham, MA, United States, 01701

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

40.00 USD

P/E Ratio

Dividend Yield

Financials XBIO

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures XBIO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+2 500 284 USD

Last Year

+2 539 986 USD

Current Quarter

+593 261 USD

Last Quarter

+648 820 USD

Current Year

+2 500 284 USD

Last Year

+2 539 986 USD

Current Quarter

+593 261 USD

Last Quarter

+648 820 USD
EBITDA -5 746 008 USD
Operating Margin TTM -158.85 %
Price to Earnings
Return On Assets TTM -31.93 %
PEG Ratio
Return On Equity TTM -53.16 %
Wall Street Target Price 40.00 USD
Revenue TTM 2 582 728 USD
Book Value 3.32 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 16.10 %
Dividend Yield
Gross Profit TTM 2 582 728 USD
Earnings per share -2.38 USD
Diluted Eps TTM -2.38 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin -142.03 %

Stock Valuation XBIO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 0.35
Price Sales TTM 2.21
Enterprise Value EBITDA 1.03
Price Book MRQ 1.19

Technical Indicators XBIO

For 52 Weeks

2.20 USD 5.27 USD
50 Day MA 3.08 USD
Shares Short Prior Month 3 494
200 Day MA 3.63 USD
Short Ratio 0.62
Shares Short 3 489
Short Percent 0.24 %